

## Press Release

---

# Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017

- **NCX 667's sustained IOP-lowering properties following repeated dosing in two preclinical models of glaucoma highlighted**

May 9, 2017  
Sophia Antipolis, France

**Nicox S.A.** (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced a poster presentation highlighting scientific data for NCX 667, a novel nitric oxide (NO) donating compound, at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting, one of the key scientific events in the ophthalmology calendar, being held May 7-11, 2017 in Baltimore, Maryland, United States.

Synthesized by Nicox, NCX 667 is the lead compound of a new class of next-generation stand-alone NO donors, which is designed to optimize NO dosing when administered alone or in combination with standard-of-care treatments to enable robust intraocular pressure (IOP)-lowering in patients with open-angle glaucoma or ocular hypertension.

The ARVO 2017 abstract by Dr. Elena Bastia, *et al.* describes preclinical results obtained following repeated dosing with NCX 667 in rabbit and non-human primate models of ocular hypertension and glaucoma. The data demonstrate rapid and sustained IOP lowering with no signs of tachyphylaxis or ocular discomfort.

**Dr. Michael Bergamini, Chief Scientific Officer and Executive Vice President at Nicox, commented:** *"A wealth of experimental and clinical data support the role of NO in lowering IOP by increasing aqueous humor outflow through relaxation of the trabecular meshwork and Schlemm's canal. NCX 667 is a novel NO donor that has been shown to effectively lower IOP in rabbit and non-human primate models following single administration. The data presented at ARVO this year demonstrate that regardless of the experimental paradigm used, repeated dosing with NCX 667 consistently lowers IOP over several days of dosing, maintaining efficacy while lacking signs of ocular discomfort."*

Open-angle glaucoma is a common ocular disorder affecting ~2% of the adult population over 40 years old and is the second-leading cause of blindness worldwide<sup>1</sup>.

The ARVO 2017 abstracts have been published in the meeting website located at [www.arvo.org/AM/Program/](http://www.arvo.org/AM/Program/) and details for the poster presentation are as follows:

**Title:** Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma

**Date and time:** Monday May 8, 2017 from 3:45pm to 5:30pm ET

**Presenter:** Elena Bastia, Nicox Research Institute

**Session:** Clinical trials and drug studies

**Abstract n° 2106, Poster n° A0167**

**Location:** 2017 ARVO Annual Meeting, Baltimore, Maryland (USA)

## About NCX 667

Previous promising results in two preclinical models of ocular hypertension and glaucoma were presented at ARVO in 2015 and 2016. In both models, NCX 667 appeared well-tolerated and effective in reducing IOP. In 2015, results were selected by the ARVO Annual Meeting Program Committee as a 'Hot Topic', representing the newest and most innovative research being conducted.

### Notes:

1. Glaucoma, Open-angle - <https://nei.nih.gov/eyedata/glaucoma>, accessed February 13, 2017

## About Nicox

---

Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: [www.nicox.com](http://www.nicox.com).

## Analyst coverage

---

Bryan, Garnier & Co	Michael Chane-Du	Paris, France
Invest Securities	Martial Descoutures	Paris, France
Gilbert Dupont	Damien Choplain	Paris, France
Stifel	Christian Glennie	London, UK



## Upcoming financial and business conferences

---

May 22-23	BioEquity Europe	Paris, France
May 30	Gilbert Dupont 15 <sup>th</sup> Annual Healthcare Conference	Paris, France
June 19-22	2017 BIO International Convention	San Diego, US
September 25-27	Cantor Fitzgerald's 3rd Annual Healthcare Conference	New York; US

## Contacts

---

### Nicox

Gavin Spencer,  
Executive Vice President Corporate Development  
T +33 (0)4 97 24 53 00  
[communications@nicox.com](mailto:communications@nicox.com)

### Investor Relations

Europe  
NewCap  
Julien Perez, Valentine Brouchet  
T +33 (0)1 44 71 94 94  
[nicox@newcap.eu](mailto:nicox@newcap.eu)

### United States

Argot Partners  
Melissa Forst  
T +1 (212) 600-1902  
[melissa@argotpartners.com](mailto:melissa@argotpartners.com)

### Media Relations

United Kingdom  
Jonathan Birt  
T +44 7860 361 746  
[jonathan.birt@gmail.com](mailto:jonathan.birt@gmail.com)

### France

NewCap  
Nicolas Merigeau  
T +33 (0)1 44 71 94 98  
[nicox@newcap.eu](mailto:nicox@newcap.eu)

### United States

Argot Partners  
Eliza Schleifstein  
T +1 (917) 763-8106  
[eliza@argotpartners.com](mailto:eliza@argotpartners.com)

## Disclaimer

---

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

### **Nicox S.A.**

Drakkar 2

Bât D, 2405 route des Dolines

CS 10313, Sophia Antipolis

06560 Valbonne, France

T +33 (0)4 97 24 53 00

F +33 (0)4 97 24 53 99